Use of Recombinant Mitogillin for Improved Serodiagnosis of<i>Aspergillus fumigatus</i>-Associated Diseases

Weig, Michael; Frosch, Matthias; Tintelnot, Kathrin; Haas, A. R. C.; Groß, Uwe; Linsmeier, Bernd; Heesemann, Jürgen

doi:10.1128/jcm.39.5.1721-1730.2001

Cited by 58 publications

(44 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The major difficulty in the biological diagnosis of ABPA remains the lack of standardization of the methods, as well as of the antigens used. Recombinant technology is known to enhance the reproducibility of antigen production (7,8,17,24). For this reason, six A. fumigatus recombinants are now commercially available for specific antibody detection.…”

Section: Discussionmentioning

confidence: 99%

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Fricker‐Hidalgo

Coltey

Llerena

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Allergic bronchopulmonary aspergillosis (ABPA) is a frequent complication in cystic fibrosis patients. The diagnosis remains difficult and requires a combination of clinical, radiological, biological, and mycological criteria. The aim of this study was to analyze the added value of two recombinant antigens, rAspf4 and rAspf6, associated with the detection of specific IgG; precipitins; total IgE; and Aspergillus fumigatus in sputum for the diagnosis of ABPA. In a retrospective study, we determined the specific IgE responses to these recombinants in 133 sera of 65 cystic fibrosis patients. We selected an average of five serum samples from each of the 17 patients with ABPA (13 proven and 4 probable ABPA) and from 3 patients with Aspergillus bronchitis and rhinosinusitis. One serum sample for the 45 patients without ABPA was tested. The sensitivity of specific IgE detection against rAspf4 calculated per patient (92.3%) was significantly higher (P < 0.05) than that of rAspf6 (53.8%). When rAspf4 IgE detection was associated with anti-Aspergillus IgG enzyme-linked immunosorbent assay (ELISA) and precipitin detection, the sensitivity rose to 100%. The specificities of rAspf4 and rAspf6 IgE detection were 93.7% and 91.6%, respectively. Other diagnostic criteria had slightly lower specificities (87.5% for anti-Aspergillus IgG ELISA, 89.6% for precipitins, 84.4% for total IgE, and 85.0% for positive A. fumigatus culture in sputum). In conclusion, this retrospective study showed the relevance of rAspf4 IgE detection, in combination with other biological markers (Aspergillus IgG ELISA, precipitins, and total IgE), for improving the biological diagnosis of ABPA.

show abstract

Section: Discussionmentioning

confidence: 99%

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Fricker‐Hidalgo

Coltey

Llerena

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Asp f 1 (GenBank accession no. P67875 and AAB07779) was expressed from the pQEMW1 plasmid, kindly provided by Frank Ebel and Jürgen Heesemann at the LMU Munich, Germany, by use of an M15 Escherichia coli host strain containing the repressor plasmid pREP4 (QIAGEN) as described previously (45). Recombinant, His-tagged Ubc9 was a gift from Jing Song and Yuan Chen and has been described earlier (30).…”

Section: Methodsmentioning

confidence: 99%

Vaccinations with Recombinant Variants of Aspergillus fumigatus Allergen Asp f 3 Protect Mice against Invasive Aspergillosis

Ito¹,

Lyons²,

Hong³

et al. 2006

Infect Immun

View full text Add to dashboard Cite

A vaccine that effectively protects immunocompromised patients against invasive aspergillosis is a novel approach to a universally fatal disease. Here we present a rationale for selection and in vivo testing of potential protein vaccine candidates, based on the modification of an immunodominant fungal allergen for which we demonstrate immunoprotective properties. Pulmonary exposure to viable Aspergillus fumigatus conidia as well as vaccination with crude hyphal extracts protects corticosteroid-immunosuppressed mice against invasive aspergillosis (J.

show abstract

“…In addition, an inhibition ELISA against developed with a sensitivity of 16-90%, a specificity of 76-100%, ppv of 59% and npv of 97% for IA [45,55]. Recently, the 18 kDa protein mitogillin has been isolated from A. fumigatus, and a role for this antigen in the serodiagnosis of IPA has been suggested [56]. Sensitivity of antigen testing is dependent on the spread of the disease.…”

Section: Laboratory Studiesmentioning

confidence: 99%

Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients

et al. 2001

View full text Add to dashboard Cite

Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. F. Reichenberger, J.M. Habicht, A. Gratwohl, M. Tamm. #ERS Journals Ltd 2002. ABSTRACT: Invasive pulmonary aspergillosis is a major cause of morbidity and mortality in neutropenic patients.Microbiological and serological tests are of limited value. The diagnosis should be considered in neutropenic patients with fever not responding to antibiotics, and typical findings on thoracic computed tomography scan. Whenever possible, diagnosis should be confirmed by tissue examination. Newer techniques, such as polymerase chain reaction may change the current diagnostic approach.Therapeutic strategies consist of prophylaxis in risk groups and the early application of antifungal agents in suspected or probable disease. Amphotericin B as desoxycholate or lipid formulation is the current standard medication in invasive infection, although it has major side effects. Its role is challenged by the new azole derivates, such as itraconazole and voriconazole, and the new echinocandins. Additional therapies with cytokines, such as granulocyte macrophage colony stimulating factor and interferon-c, and with granulocyte transfusions are under evaluation. In selected cases lung resection is of proven diagnostic and therapeutic value.This paper analyses the current understanding of the pathogenesis and epidemiology of invasive aspergillosis and reviews the actual diagnostic and therapeutic strategies for invasive pulmonary aspergillosis in neutropenic patients.

show abstract

Use of Recombinant Mitogillin for Improved Serodiagnosis ofAspergillus fumigatus-Associated Diseases

Cited by 58 publications

References 35 publications

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Recombinant Allergens Combined with Biological Markers in the Diagnosis of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients

Vaccinations with Recombinant Variants of Aspergillus fumigatus Allergen Asp f 3 Protect Mice against Invasive Aspergillosis

Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients

Contact Info

Product

Resources

About